Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $2.53 in the prior trading day, BioXcel Therapeutics Inc (NASDAQ: BTAI) closed at $2.55, up 0.79%. In other words, the price has increased by $0.79 from its previous closing price. On the day, 1.31 million shares were traded. BTAI stock price reached its highest trading level at $2.615 during the session, while it also had its lowest trading level at $2.48.
Ratios:
Our goal is to gain a better understanding of BTAI by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.74 and its Current Ratio is at 0.76.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for the company, UBS on February 21, 2024, Downgraded its rating to Neutral and sets its target price to $4 from $9 previously.
On August 15, 2023, Mizuho Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $40 to $4.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 16 ’24 when O’Neill Vincent sold 165 shares for $0.35 per share. The transaction valued at 58 led to the insider holds 19,957 shares of the business.
Mehta Vimal sold 3,117 shares of BTAI for $1,131 on Dec 16 ’24. The CEO and President now owns 59,605 shares after completing the transaction at $0.36 per share. On Dec 16 ’24, another insider, Steinhart Richard I, who serves as the Chief Financial Officer of the company, sold 577 shares for $0.36 each. As a result, the insider received 207 and left with 20,932 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BTAI now has a Market Capitalization of 50099340 and an Enterprise Value of 128625696. For the stock, the TTM Price-to-Sale (P/S) ratio is 57.59. Its current Enterprise Value per Revenue stands at 148.186 whereas that against EBITDA is -2.58.
Stock Price History:
The Beta on a monthly basis for BTAI is 0.22, which has changed by -0.7128378 over the last 52 weeks, in comparison to a change of 0.1719923 over the same period for the S&P500. Over the past 52 weeks, BTAI has reached a high of $13.28, while it has fallen to a 52-week low of $1.17. The 50-Day Moving Average of the stock is -28.19%, while the 200-Day Moving Average is calculated to be -14.48%.
Shares Statistics:
The stock has traded on average 9.68M shares per day over the past 3-months and 1262170 shares per day over the last 10 days, according to various share statistics. A total of 19.65M shares are outstanding, with a floating share count of 18.88M. Insiders hold about 3.89% of the company’s shares, while institutions hold 8.40% stake in the company. Shares short for BTAI as of 1757894400 were 1443374 with a Short Ratio of 0.15, compared to 1755216000 on 1517065. Therefore, it implies a Short% of Shares Outstanding of 1443374 and a Short% of Float of 7.539999999999999.
Earnings Estimates
. The current market rating for BioXcel Therapeutics Inc (BTAI) reflects the collective analysis of 3.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.69, with high estimates of -$0.61 and low estimates of -$0.82.
Analysts are recommending an EPS of between -$3.67 and -$8.17 for the fiscal current year, implying an average EPS of -$5.43. EPS for the following year is -$3.55, with 4.0 analysts recommending between -$2.07 and -$7.52.
Revenue Estimates
4 analysts predict $197.5k in revenue for. The current quarter. It ranges from a high estimate of $300k to a low estimate of $140k. As of. The current estimate, BioXcel Therapeutics Inc’s year-ago sales were $214kFor the next quarter, 4 analysts are estimating revenue of $270k. There is a high estimate of $400k for the next quarter, whereas the lowest estimate is $200k.
A total of 5 analysts have provided revenue estimates for BTAI’s current fiscal year. The highest revenue estimate was $900k, while the lowest revenue estimate was $638k, resulting in an average revenue estimate of $722.79k. In the same quarter a year ago, actual revenue was $2.27MBased on 5 analysts’ estimates, the company’s revenue will be $2.69M in the next fiscal year. The high estimate is $6.08M and the low estimate is $700k.
